PALMD Antibody

What is PALMD and where is it predominantly expressed?

PALMD (palmdelphin) is a cytosolic protein encoded by the PALMD gene that belongs to the paralemmin family of proteins implicated in cytoskeletal regulation. PALMD is predominantly expressed in endothelial cells of cardiovascular tissues (particularly aortic valves) and the brain . Tissue expression analysis by qRT-PCR has shown that murine Palmd is highly expressed in lung, aortic valve, and aorta tissue, followed by liver and heart, with lower levels in spleen, skeletal muscle, and kidney .

Expression pattern analysis using single-cell RNA sequencing data from the Tabula Muris database has confirmed the endothelial-dominant expression pattern of PALMD in brain, aorta, and heart tissues . In the heart specifically, PALMD is expressed in endocardial cells and cardiomyocytes in addition to endothelial cells .

What antibodies are available for PALMD detection and what applications are they validated for?

Several commercial antibodies are available for PALMD detection, with varying applications and host species:

The ProteinTech 16531-1-AP antibody has been widely used in published research for multiple applications, including immunofluorescence studies of dendrite morphology and investigating PALMD's role in uveal melanoma metastasis .

What are the recommended dilutions for PALMD antibodies in different applications?

Based on published protocols and manufacturer recommendations, the following dilutions are suggested for optimal results with PALMD antibodies:

Note: It is recommended to titrate antibodies in each specific experimental system to obtain optimal results, as sensitivity may vary between tissue types and experimental conditions .

How should I optimize Western blot protocols for PALMD detection?

For optimal Western blot detection of PALMD:

• Sample preparation: Use RIPA buffer for cell lysis and collect total protein by centrifugation at 12,000g at 4°C for 10 minutes .

• Protein quantification: Measure protein concentration using a BCA assay kit.

• SDS-PAGE separation: PALMD has a calculated molecular weight of 63 kDa but is typically observed at approximately 80 kDa on SDS-PAGE gels .

• Membrane transfer: Use PVDF membranes for optimal protein binding.

• Blocking: Block with 5% skimmed milk for 90 minutes at room temperature .

• Primary antibody incubation: Dilute anti-PALMD antibody (e.g., ProteinTech 16531-1-AP) at 1:500-1:2000 and incubate overnight at 4°C .

• Secondary antibody: Use appropriate HRP-conjugated secondary antibody (anti-rabbit IgG) at recommended dilution for 2 hours at room temperature.

• Detection: Visualize using an enhanced chemiluminescence system.

PALMD has been successfully detected in various samples including human cell lines (HeLa), mouse lung tissue, and cardiac tissues .

What protocol should I follow for immunoprecipitation of PALMD and its binding partners?

For successful immunoprecipitation of PALMD and associated proteins:

• Cell/tissue preparation: Lyse cells or tissues in an appropriate IP buffer containing protease inhibitors.

• Pre-clearing: Pre-clear lysates with protein A/G beads to reduce non-specific binding.

• Antibody binding: Incubate lysates with 0.5-4.0 μg of anti-PALMD antibody (e.g., ProteinTech 16531-1-AP) per 1.0-3.0 mg of total protein .

• Immunoprecipitation: Add protein A/G beads and incubate overnight at 4°C with gentle rotation.

• Washing: Wash beads thoroughly with IP buffer to remove non-specific interactions.

• Elution: Elute bound proteins by boiling in SDS sample buffer.

• Analysis: Analyze by SDS-PAGE followed by immunoblotting.

This protocol has been successfully used to identify PALMD-binding partners, including TNIP1 in valvular endothelial cells and Pdlim5 in neuronal cells . The Pdlim5:PALMD complex has been confirmed through both co-immunoprecipitation and proximity ligation assay (PLA) .

How can I optimize immunofluorescence protocols for PALMD detection in different cell types?

For optimal immunofluorescence detection of PALMD:

• Cell preparation: Culture cells on appropriate coverslips or use tissue cryosections at optimal thickness.

• Fixation: Fix cells/tissues with 4% paraformaldehyde for 15-20 minutes at room temperature.

• Permeabilization: Permeabilize with 0.1-0.5% Triton X-100 for 5-10 minutes.

• Blocking: Block with 5% normal serum (matching secondary antibody species) for 1 hour.

• Primary antibody: Incubate with anti-PALMD antibody (ProteinTech 16531-1-AP) at 1:50-1:200 dilution overnight at 4°C .

• Secondary antibody: Incubate with fluorophore-conjugated secondary antibody (e.g., Alexa Fluor 488 or 555 anti-rabbit) at 1:500-1:1000 for 1-2 hours at room temperature.

• Nuclear staining: Counterstain nuclei with DAPI.

• Mounting: Mount with anti-fade mounting medium.

PALMD immunofluorescence has revealed broad cytoplasmic distribution in HUVECs and valve endothelial cells , and has been used to study subcellular localization in neuronal dendrites when co-stained with Pdlim5 .

How can I investigate PALMD's role in endothelial cell function and mechanobiology?

PALMD has been implicated in endothelial cell mechanotransduction and nuclear resilience to mechanical stress . To investigate these functions:

• Shear stress experiments: Use parallel plate flow chambers or microfluidic devices to expose endothelial cells to laminar or oscillatory flow conditions.

• PALMD silencing: Implement siRNA knockdown of PALMD in endothelial cells (e.g., HUVECs or valve endothelial cells).

• Assessment of endothelial-to-mesenchymal transition (EndMT):

  • Analyze expression of EndMT markers (CD31, VE-cadherin, α-SMA, FSP1) by immunofluorescence and qRT-PCR

  • Evaluate cell morphology changes

  • Assess extracellular matrix production

• Nuclear mechanics assessment:

  • Analyze nuclear morphology (size, shape, envelope integrity)

  • Evaluate nucleocytoplasmic transport

  • Assess nuclear deformation under mechanical stress

Research has shown that PALMD-silenced valvular endothelial cells are prone to oscillatory shear stress-induced endothelial-to-mesenchymal transition, suggesting PALMD's protective role against valvular disease progression .

What approaches can I use to study PALMD interactions with the NF-κB signaling pathway?

PALMD has been shown to interact with the NF-κB signaling pathway through TNIP1 (TNFAIP3 interaction protein 1) . To investigate this interaction:

• Protein interaction studies:

  • Co-immunoprecipitation with PALMD antibodies followed by immunoblotting for NF-κB pathway components

  • Proximity ligation assay to visualize interactions in situ

  • Mass spectrometry analysis of PALMD immunoprecipitates

• Functional assays:

  • PALMD knockdown/overexpression followed by assessment of NF-κB activation

  • Luciferase reporter assays for NF-κB transcriptional activity

  • Analysis of IκB phosphorylation and degradation

  • Nuclear translocation of p65/RelA by immunofluorescence

• Ubiquitination analysis:

  • Ubiquitination assays for IKBKG (NEMO) after PALMD silencing

  • Assessment of TNFAIP3-dependent deubiquitinating activity

Research has shown that loss of PALMD impairs TNFAIP3-dependent deubiquitinating activity and promotes the ubiquitination of IKBKG and subsequent NF-κB activation , suggesting a mechanism for PALMD's protective effects in valvular disease.

How can I use PALMD antibodies to investigate its role in disease models?

PALMD has been implicated in several pathological conditions, including calcific aortic valve disease and uveal melanoma metastasis . To investigate PALMD's role in these contexts:

• Animal models:

  • Analyze PALMD expression in Palmd-deficient mice, which manifest increased aortic valve peak velocity, thickened aortic valve leaflets, and excessive extracellular matrix deposition in advanced age

  • Perform immunohistochemistry on valve tissue sections to assess PALMD localization and expression levels

  • Implement adeno-associated virus-mediated PALMD overexpression to ameliorate aortic valvular remodeling

• Cancer studies:

  • Analyze PALMD expression in primary tumors versus metastatic lesions

  • Correlate PALMD levels with clinical outcomes in cancer patients

  • Perform functional studies of PALMD silencing/overexpression in cancer cell lines

  • Investigate transcriptional regulation of PALMD by factors such as ZNF263

• Human tissue studies:

  • Compare PALMD expression in healthy versus diseased human tissues

  • Correlate PALMD levels with genetic variants (e.g., SNP rs7543130) associated with disease risk

  • Perform co-localization studies with markers of disease progression

What control experiments should I include when working with PALMD antibodies?

To ensure reliable and reproducible results with PALMD antibodies:

• Antibody validation controls:

  • Include PALMD-deficient samples (knockout cells/tissues or siRNA-treated samples)

  • Use multiple antibodies targeting different epitopes when possible

  • Include isotype controls in immunoprecipitation experiments (e.g., rabbit IgG for rabbit polyclonal antibodies)

• Expression verification:

  • Confirm PALMD expression levels by multiple methods (qRT-PCR, Western blot, immunofluorescence)

  • Validate antibody specificity by observing the correct molecular weight band (approximately 80 kDa)

• Localization controls:

  • Use co-localization with known markers to confirm subcellular localization

  • Include positive control tissues with known high PALMD expression (lung, aortic valve, brain endothelial cells)

• Functional validation:

  • Rescue experiments after PALMD knockdown to confirm specificity of observed phenotypes

  • Use multiple siRNAs targeting different regions of PALMD mRNA to rule out off-target effects

Why might I observe different molecular weights for PALMD in Western blot analysis?

PALMD has a calculated molecular weight of 63 kDa based on its amino acid sequence, but is typically observed at approximately 80 kDa on SDS-PAGE gels . This discrepancy may be attributed to:

• Post-translational modifications: PALMD may undergo modifications such as phosphorylation, which can alter its migration pattern.

• Splice variants: Two main PALMD splice variants have been identified:

  • Cytosolic PALMD-KKVI form (predominant, approximately 300-fold more abundant in HUVECs)

  • Membrane-anchored PALMD-CaaX form

• Sample preparation: Different lysis buffers and preparation methods may affect protein denaturation and migration.

• Tissue-specific differences: The observed molecular weight may vary slightly between different tissues and cell types.

If encountering unexpected bands, validate with multiple antibodies and consider analyzing PALMD expression at the mRNA level to confirm splice variant expression.

What are common pitfalls in immunoprecipitation experiments with PALMD antibodies?

When performing immunoprecipitation with PALMD antibodies, researchers should be aware of these potential issues:

• Co-migration challenges: Since endogenous Pdlim5 and PALMD migrate at comparable positions via SDS-PAGE, separate blots may be needed to resolve co-IPs versus self-IPs .

• Non-specific binding: Always include appropriate negative controls (isotype-matched IgG) to account for non-specific binding .

• Buffer compatibility: The PALMD:partner protein complex may have specific stability requirements. Some complexes (like PALMD:Pdlim5) have been found to be quite stable, surviving overnight incubations in cell lysis/extraction buffer .

• Antibody cross-reactivity: Validate antibody specificity by immunoprecipitating from PALMD-depleted samples as negative controls.

• Protein complex disruption: Overly harsh lysis conditions may disrupt protein-protein interactions. Consider using milder detergents when studying PALMD complexes.

How can I optimize PALMD detection in tissue samples with low expression levels?

For detecting PALMD in tissues with low expression levels:

• Signal amplification methods:

  • Use tyramide signal amplification (TSA) for immunohistochemistry

  • Consider more sensitive detection systems for Western blot (e.g., chemiluminescence substrates with extended sensitivity)

• Sample enrichment:

  • Isolate specific cell populations where PALMD is known to be expressed (e.g., endothelial cells)

  • Use subcellular fractionation to enrich for cytosolic proteins

• Antigen retrieval optimization:

  • Test multiple antigen retrieval methods (heat-induced with citrate buffer pH 6.0 or TE buffer pH 9.0)

  • Optimize retrieval time and temperature

• Antibody concentration:

  • Use higher concentrations of primary antibody (within the recommended range)

  • Extend primary antibody incubation time (overnight at 4°C)

• Reducing background:

  • Increase blocking time and concentration

  • Use more stringent washing conditions

  • Consider using specialized blocking reagents for the tissue type

How do I interpret conflicting PALMD expression data between protein and mRNA levels?

Discrepancies between PALMD protein and mRNA expression levels may occur due to:

• Post-transcriptional regulation: PALMD mRNA may be subject to regulation by microRNAs or RNA-binding proteins that affect translation efficiency.

• Protein stability: Differences in protein turnover rates between tissues or conditions may lead to accumulation or depletion of PALMD protein independent of mRNA levels.

• Technical considerations:

  • Antibody sensitivity and specificity issues

  • mRNA detection method limitations

  • Sample preparation differences

• Biological context: In disease states, the relationship between mRNA and protein expression may be altered due to stress responses or pathological processes.

To resolve such discrepancies:

• Use multiple antibodies and detection methods

• Assess protein stability with cycloheximide chase experiments

• Investigate potential post-transcriptional regulators

• Consider the biological context and disease state

Research has shown that patients with calcific aortic valve stenosis carrying the single nucleotide polymorphism rs7543130 express reduced PALMD mRNA levels in valve endothelial cells, correlating with altered cellular phenotypes , indicating the importance of considering both protein and transcript levels in PALMD studies.

How can new antibody technologies enhance PALMD research?

Emerging antibody technologies that could advance PALMD research include:

• Single-domain antibodies (nanobodies): These smaller antibody fragments could provide improved access to epitopes and potentially better penetration in tissue samples.

• Recombinant antibody engineering: Custom-designed recombinant antibodies with enhanced specificity for PALMD could reduce background and cross-reactivity issues.

• Proximity-dependent labeling: Antibody conjugates that enable BioID or APEX2 proximity labeling could help identify novel PALMD interactors in specific subcellular compartments.

• Antibody-based biosensors: Development of FRET-based or other conformational biosensors could allow real-time monitoring of PALMD conformational changes or interactions in living cells.

• AI-assisted antibody design: Approaches like the PALM-H3 system (Pre-trained Antibody generative large Language Model) could potentially be adapted to design highly specific antibodies against challenging PALMD epitopes.

What are promising approaches for studying PALMD in complex tissue environments?

Advanced methods for investigating PALMD in complex tissues include:

• Spatial transcriptomics combined with immunofluorescence: This approach can correlate PALMD protein localization with transcriptional profiles in tissue sections.

• Multi-parameter imaging:

  • Multiplexed immunofluorescence with spectral unmixing

  • Imaging mass cytometry for simultaneous detection of PALMD and dozens of other markers

  • CODEX (CO-Detection by indEXing) for highly multiplexed protein detection

• 3D cell culture models:

  • Organoid cultures from tissues with high PALMD expression

  • Microfluidic organs-on-chips with mechanical stimulation capabilities

  • 3D bioprinted tissues with defined endothelial components

• In vivo imaging:

  • Development of fluorescently tagged PALMD variants for intravital microscopy

  • Creation of PALMD reporter mouse models

• Single-cell protein analysis:

  • Single-cell Western blot techniques

  • Mass spectrometry-based single-cell proteomics